Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease

Circulation

Volumn 93, Issue 1, 1996, Pages 106-110

  Lundgren, Craig H ^a   Brown, Steven L ^a   Nordt, Thomas K ^a   Sobel, Burton E ^b   Fujii, Satoshi ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

adipocyte; obesity; plasminogen activator inhibitor; risks

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOCYTE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CORONARY RISK; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0030066399     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.1.106     Document Type: Article

References (42)

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation. 1983; 67:968-977.
2. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1988;112:432-437.
3. Bjorntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10: 493-496.
4. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Coller B, ed. Progress in Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders; 1989:87-115.
5. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism. 1986;35: 250-253.
6. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during early hours of transmural infarction. N Engl J Mad. 1980;303: 897-902.
7. Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH. Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Haemost. 1988;14:189-195.
8. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol. 1989;159:97-106.
9. Gray RP, Patterson DLH, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb. 1993;13:415-420.
10. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
12. Weiss GH, Rosen OM, Rubin CS. Regulation of fatty acid synthetase concentration and activity during adipocyte differentiation. J Biol Chem. 1980;255:4751-4757.
13. Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, Mezzetti A, Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb. 1994;14:299-304.
14. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb. 1993;13:1822-1828.
15. Lucore CL, Fujii S, Wun T-C, Sobel BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem. 1988;263: 15845-15848.
16. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89: 321-330.
17. Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1. Mol Cell Biol. 1990;10:1265-1269.
18. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992; 12:647-656.
19. Heikki FM, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä E. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
20. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type 1. Circulation. 1992;85:1888-1893.
21. Avellone G, DiGarbo V, Cordova R, Ranelli G, DeSimone R, Bompiani G. Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Therapeutic Res. 1992; 52:338-348.
22. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91:1952-1958.
23. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol. 1993;142: 59-70.
24. Palareti G, Legnani C, Poggi M, Parenti M, Babini AC, Biagi R, Baraldi L, Luchi A, Capelli M, Coccheri S. Prolonged very low calorie diet in obese subjects reduces factor VII and PAI but not fibrinogen levels. Fibrinolysis. 1994;8:16-21.
25. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol. 1987;105:1039-1045.
26. Fujii S, Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation. 1991;83:645-651.
27. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266: 9419-9427.
28. Fujii S, Lucore CL, Hopkins WE, Billadello JJ, Sobel BE. Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications. Am J Cardiol. 1989;63: 1505-1511.
29. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cell culture. Infect Immun. 1986;52:725-729.
30. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985;75:818-824.
31. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium: effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988;263:5797-5803.
32. van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988;72:1467-1473.
33. Silva CL, Foss NT. Tumor necrosis factor in leprosy patients. J Infect Dis. 1989;159:787-790.
34. Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Pctersen E, Slymen DJ, Salmon SE. Raised serum level of tumor necrosis factor in parasitic infections. Lancet. 1986;2:1364-1365.
35. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost. 1994;72: 44-53.
36. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC study. Circulation. 1995;91:284-290.
37. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MD, Atlan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab. 1987;13:331-336.
38. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism. 1990;39:1044-1048.
39. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314-325.
40. Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Hormone-like activity of human thrombin. Ann N Y Acad Sci. 1986;485:335-348.
41. Jawlen A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
42. Majack RA, Cook SC, Bomstein P. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci USA. 1988;82:9050-9054.